| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Research Abstract |
In the present study, we aimed to develop survivin targeting radiopharmaceuticals for the realization of tumor specific nuclear medicine diagnosis. Because 4, 6-diaryl pyridinones have been reported to possess high affinity for dimer site of survivin protein, several derivatives were synthesized and evaluated. In the binding assay using the cancer cells with high expression of survivin, these 4, 6-diaryl pyridinone derivatives showed high membrane permeability and similar accumulation pattern with survivin expression site. Furthermore in vivo biodistribution study revealed that[^<125> I] 4, 6-diaryl pyridinones showed moderate blood retention and rapid clearance by normal tissues. The results of this study illustrate that these 4, 6-diaryl pyridinones might be promising tumor imaging agents for survivin.
|
